Royalty Pharma plc — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Q3 2026 Portfolio Receipts reached $890M (up 9% YoY); Royalty Receipts grew 9% to $883M, driven by Tremfya, Voranigo, Evrysdi, and Imdelltra. Full-year 2026 guidance raised to $3,500M–$3,550M (prior $3,400M–$3,500M), reflecting 10–11% expected Royalty Receipts growth. Capital Deployment was $362M in Q3; $1.2B year-to-date against $1.9B announced transaction value. New royalty acquisitions: $100M each for Zoryve (Arcutis) and Mimrylo (Takeda); up to $425M for cliramitug (AstraZeneca). Non-cash impairment charge of $150M recorded for pelacarsen.
Why this rating
Guidance raise and solid YoY growth are positive, but modest in absolute terms (~3% of company market cap). Impairment signals portfolio risk; routine quarterly results despite favorable guidance.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.